June 8, 2017 — Today, the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is…Original Article
FDA Requests Removal of Opana ER for Risks Related to Abuse
